We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy Chemours Company (CC) Stock Now
Read MoreHide Full Article
We believe that The Chemours Company’s (CC - Free Report) financial performance in second-quarter 2017 as well as solid future prospects makes it a good bet for investors now.
The company currently boasts a Zacks Rank #1 (Strong Buy).
In the last three months, the company’s shares have yielded 5.4% return, outperforming 3.1% gain recorded by the industry it belongs to.
Why the Upgrade?
Chemours exhibited strong financial performance in second-quarter 2017. Its earnings came in 45% above the year-ago tally while revenues grew 15% over the same period. Top-line results were driven by healthy sales growth in Titanium Technologies and Fluoroproducts segments. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) improved on volume and pricing improvements.
In 2017, the company is poised to gain from improving end markets conditions, especially in coatings, plastics, papers, air conditioning, refrigeration, automotive, aerospace, consumer, wire & cable, electronics and telecommunications. Also, its strategic initiatives, intended to reduce costs, expansion of Altamira plant (completed) and Corpus Christi (ongoing) as well as increased use of Opteon will be beneficial. For 2017, the company raised its adjusted EBITDA projection to $1.3−$1.4 billion from the earlier forecast of $1.2−$1.3 billion.
Additionally, in June, the company started constructing a new Mining Solutions manufacturing facility in Mexico. The new facility will enable it to leverage benefits from the growing demand for solid sodium cyanide from the mining industry.
Also, earnings estimates for the stock were revised upward by a couple of analysts in the last 30 days, reflecting positive sentiments for Chemours’ future prospects. The Zacks Consensus Estimate for 2017 improved 3.7% from $3.50 to $3.63 while that for 2018 increased 13.8% from $4.00 to $4.55.
Koninklijke DSM’s earnings estimates for 2017 and 2018 improved in the last 60 days. Also, its earnings are projected to grow 7.1% in the next three to five years.
Arkema SA’s earnings estimates for 2017 and 2018 improved in the last 60 days. Its earnings are projected to grow 12.8% in the next three to five years.
Asahi Kasei Corporation’s earnings estimates for fiscal 2017 and fiscal 2018 were revised upward in the last 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Here's Why You Should Buy Chemours Company (CC) Stock Now
We believe that The Chemours Company’s (CC - Free Report) financial performance in second-quarter 2017 as well as solid future prospects makes it a good bet for investors now.
The company currently boasts a Zacks Rank #1 (Strong Buy).
In the last three months, the company’s shares have yielded 5.4% return, outperforming 3.1% gain recorded by the industry it belongs to.
Why the Upgrade?
Chemours exhibited strong financial performance in second-quarter 2017. Its earnings came in 45% above the year-ago tally while revenues grew 15% over the same period. Top-line results were driven by healthy sales growth in Titanium Technologies and Fluoroproducts segments. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) improved on volume and pricing improvements.
In 2017, the company is poised to gain from improving end markets conditions, especially in coatings, plastics, papers, air conditioning, refrigeration, automotive, aerospace, consumer, wire & cable, electronics and telecommunications. Also, its strategic initiatives, intended to reduce costs, expansion of Altamira plant (completed) and Corpus Christi (ongoing) as well as increased use of Opteon will be beneficial. For 2017, the company raised its adjusted EBITDA projection to $1.3−$1.4 billion from the earlier forecast of $1.2−$1.3 billion.
Additionally, in June, the company started constructing a new Mining Solutions manufacturing facility in Mexico. The new facility will enable it to leverage benefits from the growing demand for solid sodium cyanide from the mining industry.
Also, earnings estimates for the stock were revised upward by a couple of analysts in the last 30 days, reflecting positive sentiments for Chemours’ future prospects. The Zacks Consensus Estimate for 2017 improved 3.7% from $3.50 to $3.63 while that for 2018 increased 13.8% from $4.00 to $4.55.
Chemours Company (The) Price and Consensus
Chemours Company (The) Price and Consensus | Chemours Company (The) Quote
Other Stocks to Consider
Chemours has a market capitalization of approximately $8.5 billion. Other stocks worth considering in the industry include Koninklijke DSM NV , Arkema SA (ARKAY - Free Report) and Asahi Kasei Corporation (AHKSY - Free Report) . All these stocks sport a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Koninklijke DSM’s earnings estimates for 2017 and 2018 improved in the last 60 days. Also, its earnings are projected to grow 7.1% in the next three to five years.
Arkema SA’s earnings estimates for 2017 and 2018 improved in the last 60 days. Its earnings are projected to grow 12.8% in the next three to five years.
Asahi Kasei Corporation’s earnings estimates for fiscal 2017 and fiscal 2018 were revised upward in the last 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>